Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.54 |
| ▸ | CETP | P11597 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4604120 | 0.93 | ACLY (0.58) | ACLYALDH1A1HDAC1HDAC2HDAC3 | |
| SCHEMBL4602392 | 0.87 | HDAC1 (0.56) | ACLYALDH1A1HDAC1HDAC2HDAC3 | |
| SCHEMBL7814976 | 0.84 | ALDH1A1 (0.68) | ALDH1A1HDAC1HDAC2HDAC3HPGD | |
| SCHEMBL11732563 | 0.84 | ALDH1A1 (0.68) | ALDH1A1HDAC1HDAC2HDAC3HPGD | |
| SCHEMBL11734795 | 0.82 | ALDH1A1 (0.70) | ALDH1A1HDAC1HDAC2HDAC3HPGD | |
| SCHEMBL1308249 | 0.82 | HSD17B10 (0.64) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL2274782 | 0.82 | ALDH1A1 (0.54) | ALDH1A1HDAC1HDAC2HDAC3HPGD | |
| SCHEMBL2272904 | 0.82 | KDM4E (0.57) | ALDH1A1HDAC1HDAC2HDAC3HPGD | |
| SCHEMBL3928302 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HDAC1HDAC2HDAC3HPGD | |
| SCHEMBL4604309 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HDAC1HDAC2HDAC3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | ACLY 653/4885ALDH1A1 645/4885HDAC1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.